Silver Leaf acquires 10% stake in Biocon’s research arm ‘Syngene’

Silver Leaf Oak (Mauritius) (Silver Leaf), an investment vehicle advised by India Value Fund Advisors (IVFA) has agreed to acquire a minority 10% stake in Biocon’s Research Services subsidiary - Syngene International (Syngene). Silver Leaf will acquire the stake from Biocon Research (BRL), a wholly owned subsidiary of Biocon at a valuation of Rs 3800 crore.

Post the completion of this transaction, Biocon and BRL will jointly hold 85.54% stake in Syngene. The above transaction is however subject to standard condition precedents including regulatory approvals.

Biocon is India’s largest and Asia's leading biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.